YIYoshiaki Ito

Yoshiaki Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshiaki Ito has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gastric cancer

    by Yoshiaki Ito, Khay Guan Yeoh

    Etiology Although the worldwide incidence of gastric cancer has declined in recent years, it is still the second most frequent cause of cancer-related death in the world. Environmental factors play critical roles in the pathogenesis of gastric cancer, with the major risk factors being Helicobacter pylori (H. pylori) infection, diet, and smoking (1). H. pylori infection is the most important single risk factor for gastric cancer development and has been defined as a Class 1 carcinogen by the World Health Organization (WHO). Populations with high incidences of gastric cancer can be found in geographic areas with high prevalence of H. pylori infection. High salt intake, often due to traditional diet in the form of salted fish, is the best-documented dietary risk factor for atrophic gastritis (2). Epstein–Barr virus (EBV) infection is correlated with Burkitt’s lymphoma in Africa and nasopharyngeal carcinoma in South-East Asia. In addition, this virus has been recognized as an etiological agent in 5–10% of gastric cancers (3). Infectious agents, therefore, play important causative roles in gastric carcinogenesis.

  • Open Access

    Loss of Runx3 Is a Key Event in Inducing Precancerous State of the Stomach

    by Kosei Ito, Linda Shyue Huey Chuang, Tomoko Ito, Ti Ling Chang, Hiroshi Fukamachi, Manuel Salto–Tellez, Yoshiaki Ito


  • Open Access

    Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility

    by David T Leong, Joleen Lim, Xuewei Goh, Jitesh Pratap, Barry P Pereira, Hui Si Kwok, Saminathan Suresh Nathan, Jason R Dobson, Jane B Lian, Yoshiaki Ito, et al.

    Introduction: Metastatic breast cancer cells frequently and ectopically express the transcription factor RUNX2, which normally attenuates proliferation and promotes maturation of osteoblasts. RUNX2 expression is inversely regulated with respect to cell growth in osteoblasts and deregulated in osteosarcoma cells. Methods: Here, we addressed whether the functional relationship between cell growth and RUNX2 gene expression is maintained in breast cancer cells. We also investigated whether the aberrant expression of RUNX2 is linked to phenotypic parameters that could provide a selective advantage to cells during breast cancer progression. Results: We find that, similar to its regulation in osteoblasts, RUNX2 expression in MDA-MB-231 breast adenocarcinoma cells is enhanced upon growth factor deprivation, as well as upon deactivation of the mitogen-dependent MEK-Erk pathway or EGFR signaling. Reduction of RUNX2 levels by RNAi has only marginal effects on cell growth and expression of proliferation markers in MDA-MB-231 breast cancer cells. Thus, RUNX2 is not a critical regulator of cell proliferation in this cell type. However, siRNA depletion of RUNX2 in MDA-MB-231 cells reduces cell motility, while forced exogenous expression of RUNX2 in MCF7 cells increases cell motility. Conclusions: Our results support the emerging concept that the osteogenic transcription factor RUNX2 functions as a metastasis-related oncoprotein in non-osseous cancer cells.


    • 1 July 2010
      • Vol. 30  (7) , 2673-82

    RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.

    by Minoru Nishio, Chouhei Sakakura, Tomoyuki Nagata, Sosuke Komiyama, Atsushi Miyashita, Takuo Hamada, Yoshiaki Kuryu, Hisashi Ikoma, Takeshi Kubota, Akio Kimura, et al.

    RUNX3 is a novel gastric cancer tumor suppressor. RUNX3 promoter hypermethylation is associated with many types of cancer, including colorectal cancer. Furthermore, the RUNX3 promotor is one of the CpG island methylator phenotype (CIMP)-specific promotors. CIMP is a distinct phenotype associated with microsatellite instability (MSI) in colorectal cancer. In this study, the suitability of the quantitative analysis of RUNX3 promoter hypermethylation as a novel serum tumor marker was investigated. Moreover, we investigated the relationship between RUNX3 promoter methylation and MSI in colorectal cancer. A RUNX3 real-time quantitative methylation-specific PCR (RTQ-MSP) technique we developed was used to analyze the CpG sites in the RUNX3 promoter of 119 colorectal tumors and 344 sera from colorectal cancer patients. MSI analysis of 119 colorectal tumors was performed with five microsatellite markers (BAT25, BAT26, D5S346, D2S123, and D17S250). Proximal colon tumors exhibited significantly higher RUNX3 methylation than their paired normal tissues (p=0.0438). Analysis of the clinicopathological parameters revealed that a proximal location (p=0.0054), lymphatic invasion (p<0.0001), and an advanced pathological stage (p=0.0018) were associated with significantly higher RUNX3 methylation. Assessment of the relationship between RUNX3 methylation and tumor MSI revealed 11 out of 13 tumors with high-frequency MSI (85%) were positive for RUNX3 hypermethylation, significantly more than the tumors with low-frequency MSI or which were microsatellite stable (34%, p=0.0070). In preoperative sera from 344 colorectal cancer patients, significantly higher RUNX3 methylation was associated with lymphatic invasion (p=0.0487) and an advanced pathological stage (p=0.0466). Post-operative follow-up data revealed that recurrence cases exhibited significantly higher preoperative serum RUNX3 methylation than non-recurrence cases (p=0.0003). Concomitant analysis of carcinoembryonic antigen (CEA) levels in the preoperative sera showed that 17.7% (61/344) were CEA-negative but RUNX3 methylation-positive, which means assessing both serum RUNX3 methylation and CEA should improve diagnosis of colorectal carcinoma. RTQ-MSP-based quantification of serum RUNX3 methylation is useful for the detection and monitoring of colorectal cancer.


  • Open Access

    RUNX3 is multifunctional in carcinogenesis of multiple solid tumors

    by L S H Chuang, Y Ito

    The study of RUNX3 in tumor pathogenesis is a rapidly expanding area of cancer research. Functional inactivation of RUNX3—through mutation, epigenetic silencing, or cytoplasmic mislocalization—is frequently observed in solid tumors of diverse origins. This alone indicates that RUNX3 inactivation is a major risk factor in tumorigenesis and that it occurs early during progression to malignancy. Conversely, RUNX3 has also been described to have an oncogenic function in a subset of tumors. Although the mechanism of how RUNX3 switches from tumor suppressive to oncogenic activity is unclear, this is of clinical relevance with implications for cancer detection and prognosis. Recent developments have significantly contributed to our understanding of the pleiotropic tumor suppressive properties of RUNX3 that regulate major signaling pathways. This review summarizes the important findings that link RUNX3 to tumor suppression.


  • Claudin-1 Has Tumor Suppressive Activity and Is a Direct Target of RUNX3 in Gastric Epithelial Cells

    by Ti Ling Chang, Kosei Ito, Tun Kiat Ko, Qiang Liu, Manuel Salto–Tellez, Khay Guan Yeoh, Hiroshi Fukamachi, Yoshiaki Ito


    • 1 July 2009
      • Vol. 29  (7) , 2619-25

    Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients.

    by Chouhei Sakakura, Takuo Hamada, Koji Miyagawa, Minoru Nishio, Atushi Miyashita, Hiroyuki Nagata, Hiroshi Ida, Shujiro Yazumi, Eigo Otsuji, Tsutomu Chiba, et al.

    Using real-time quantitative methylation-specific PCR (RTQ-MSP), methylated RUNX3 sequences were quantified and the fractional concentrations of circulating tumor DNA in serum were determined, along with peripheral blood cells collected preoperatively, intraoperatively and postoperatively from 65 patients with gastric cancer. RTQ-MSP was sufficiently sensitive to detect RUNX3 methylation. Quantitative MSP data were expressed in terms of the methylation index, which was defined as the relative amount of methylated RUNX3 sequences divided by the concentration of methylated actin. High levels of methylated RUNX3 sequences were detected in the peripheral circulation of 29% (19 of 65) of the gastric cancer patients. The RUNX3 methylation index was concordant with cancer stage, histology, lymphatic and vascular invasion, and was more sensitive than carcinoembryonic antigen (CEA) as a biomarker. Twenty-nine percent (19 out of 65) of preoperative serum samples had methylated RUNX3 sequences, ranging from 5.2 to 1625955 (median quantity=43 m-index, sensitivity 95.5%, specificity 62.5%, AUC 0.8651). After surgical resection, the median RUNX3 methylation index in serum significantly decreased. These results demonstrate the clinical usefulness and effectiveness of peripheral blood RTQ-MSP for detecting and monitoring gastric cancer after treatment. Furthermore, 5 out of the 30 preoperative control samples of benign disease (cases of panperitonitis due to acute appendicitis or cholecystitis) showed transient RUNX3 methylation which decreased after the operation in accordance with recovery. Quantification of epigenetic changes in serum RUNX3 methylation using RTQ-MSP is useful for the detection and monitoring of gastric cancer.


  • RUNX3 Attenuates β-Catenin/T Cell Factors in Intestinal Tumorigenesis

    by Kosei Ito, Anthony Chee-Beng Lim, Manuel Salto-Tellez, Lena Motoda, Motomi Osato, Linda Shyue Huey Chuang, Cecilia Wei Lin Lee, Dominic Chih-Cheng Voon, Jason Kin Wai Koo, Huajing Wang, et al.

  • Open Access

    Runx3 expression in gastrointestinal tract epithelium: resolving the controversy

    by K Ito, K-I Inoue, S-C Bae, Y Ito

    We reported earlier that RUNX3 is expressed in human and mouse gastrointestinal tract (GIT) epithelium and that it functions as a tumor suppressor in gastric and colorectal tissues. However, there have been conflicting reports describing the absence of Runx3 in GIT epithelial cells. A part of the controversy may be derived from the use of a specific antibody by other groups (referred to as G-poly). Here, we show further evidence to support our earlier observations and provide a possible explanation for this apparent controversy. We generated multiple anti-RUNX3 monoclonal antibodies and found that RUNX3 antibodies recognizing the RUNX3 N-terminal region (residues 1–234) react with RUNX3 in gastric epithelial cells, whereas those recognizing the C-terminal region (beyond residue 234) did not. G-poly primarily recognizes the region beyond 234 and hence, is unable to detect Runx3 in this tissue.


  • Open Access

    Runx transcription factors in neuronal development

    by Ken-Ichi Inoue, Takashi Shiga, Yoshiaki Ito

    Runt-related (Runx) transcription factors control diverse aspects of embryonic development and are responsible for the pathogenesis of many human diseases. In recent years, the functions of this transcription factor family in the nervous system have just begun to be understood. In dorsal root ganglion neurons, Runx1 and Runx3 play pivotal roles in the development of nociceptive and proprioceptive sensory neurons, respectively. Runx appears to control the transcriptional regulation of neurotrophin receptors, numerous ion channels and neuropeptides. As a consequence, Runx contributes to diverse aspects of the sensory system in higher vertebrates. In this review, we summarize recent progress in determining the role of Runx in neuronal development.